We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+25.17%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$14.8B
AUM Growth
+$1.58B
Cap. Flow
-$1.22B
Cap. Flow %
-8.22%
Top 10 Hldgs %
44.34%
Holding
132
New
32
Increased
38
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$317M
2
CRM icon
Salesforce
CRM
+$270M
3
TMO icon
Thermo Fisher Scientific
TMO
+$259M
4
MDCO
Medicines Co
MDCO
+$221M
5
PPLI
People Inc
PPLI
+$137M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.55B
2
BRMK
Broadmark Realty Capital Inc. Common Stock
BRMK
+$754M
3
AABA
Altaba Inc
AABA
+$666M
4
BABA icon
Alibaba
BABA
+$196M
5
CTXS
Citrix Systems Inc
CTXS
+$183M

Sector Composition

Rank Sector Weight
1 Healthcare 46.6%
2 Communication Services 12.82%
3 Technology 9.97%
4 Industrials 5.05%
5 Financials 3.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INFO
26
DELISTED
IHS Markit Ltd. Common Shares
INFO
$207M 1.4%
2,743,550
-831,834
-23% -$59.2M
ASND icon
27
Ascendis Pharma A/S
ASND
$16.6B
$178M 1.2%
1,279,000
-271,000
-17% -$30.1M
SPGI icon
28
S&P Global
SPGI
$127B
$175M 1.18%
640,382
-191,932
-23% -$49.9M
GD icon
29
General Dynamics
GD
$104B
$173M 1.17%
981,365
-10,367
-1% -$1.86M
IOVA icon
30
Iovance Biotherapeutics
IOVA
$3.76B
$173M 1.17%
6,250,000
+225,000
+4% +$5.12M
ALNY icon
31
Alnylam Pharmaceuticals
ALNY
$31.6B
$167M 1.13%
1,450,000
-50,000
-3% -$4.98M
MYOK
32
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$149M 1.01%
2,050,000
+19,603
+1% +$1.19M
EXEL icon
33
Exelixis
EXEL
$13.4B
$132M 0.89%
7,500,000
+5,750,000
+329% +$97.5M
TRU icon
34
TransUnion
TRU
$16.2B
$131M 0.88%
1,527,771
+272,633
+22% +$22.7M
ENTA icon
35
Enanta Pharmaceuticals
ENTA
$392M
$108M 0.73%
1,750,000
+475,788
+37% +$29.5M
XLRN
36
DELISTED
Acceleron Pharma
XLRN
$106M 0.72%
2,000,000
-400,000
-17% -$18.2M
BRMK
37
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$91.5M 0.62%
7,174,613
-67,825,387
-90% -$754M
BMY.RT
38
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$91.4M 0.62%
+30,374,950
New +$79M
EFX icon
39
Equifax
EFX
$22.6B
$91.4M 0.62%
652,189
+17,133
+3% +$2.37M
ZGNX
40
DELISTED
Zogenix, Inc.
ZGNX
$91.2M 0.62%
1,750,000
– –
AMRN
41
Amarin Corp
AMRN
$298M
$88.4M 0.6%
206,250
+106,220
+106% +$40.3M
AXE
42
DELISTED
Anixter International Inc
AXE
$84.5M 0.57%
+917,893
New +$74.4M
ZYME icon
43
Zymeworks
ZYME
$2.05B
$77.3M 0.52%
1,700,000
-31,500
-2% -$1.14M
QGEN icon
44
Qiagen
QGEN
$9.1B
$72.8M 0.49%
+2,031,342
New +$75.5M
GRFS
45
Grifois
GRFS
$5.44B
$72.5M 0.49%
3,113,222
– –
BOLD
46
DELISTED
Audentes Therapeutics, Inc
BOLD
$71.2M 0.48%
+1,190,000
New +$44.7M
AGIO icon
47
Agios Pharmaceuticals
AGIO
$1.98B
$59.7M 0.4%
+1,250,000
New +$47.2M
GBT
48
DELISTED
Global Blood Therapeutics, Inc.
GBT
$59.6M 0.4%
750,000
-862,069
-53% -$51.1M
CCXI
49
DELISTED
ChemoCentryx, Inc.
CCXI
$59.3M 0.4%
1,500,000
-513,396
-25% -$9.01M
DCPH
50
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$59.1M 0.4%
950,000
+200,000
+27% +$9.51M
1
2
3 4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2019 Portfolio in Review

As of Q4 2019, Thomas Steyer held 132 positions worth $14.8B, up 12% from $13.2B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Thomas Steyer withdrew a net $1.22B in Q4 2019, closing 16 positions and reducing 29 holdings. Its most notable exit was Celgene Corp, an estimated $1.55B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 45% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in Salesforce worth $281M.

  • Thomas Steyer's largest Q4 2019 buy was Salesforce: 1,724,880 shares worth $281M.
  • Thomas Steyer added most to Allergan plc in Q4 2019, an estimated $317M increase.
  • Thomas Steyer's biggest Q4 2019 reduction was Broadmark Realty Capital Inc. Common Stock, cutting an estimated $754M.
  • Thomas Steyer fully exited Celgene Corp in Q4 2019, selling an estimated $1.55B.
  • Thomas Steyer's ten largest holdings make up 44% of its $14.8B portfolio in Q4 2019.
  • Thomas Steyer opened 32 new positions and closed 16 in Q4 2019.
  • Thomas Steyer's portfolio value rose 12% quarter-over-quarter to $14.8B.

Based on Farallon Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.